Naringenin is a citrus plant compound sold as a supplement for metabolic and aging support. Human evidence is small: a few trials, mostly from one group in people with fatty liver, report better cholesterol and triglyceride levels and less liver fat, the latter not yet repeated independently. Longevity, muscle, bone and brain-aging claims rest on animal and cell studies. Safety concerns are theoretical or indirect; no long-term data exist. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase and aspartate aminotransferase | Approx. 7–55 U/L and 8–48 U/L (standard reference range) | Safety check: rising values would stop use |
| Creatinine | 0.6–1.3 mg/dL (standard reference range) | Safety check: kidney function |
| LDL cholesterol, triglycerides, HDL cholesterol | No established target; track change from the individual's own baseline | Expected-change marker: lipid effect in fatty liver trial |
| Fasting glucose and insulin | Insulin approx. 2–25 µIU/mL (standard reference range); glucose: no established target, track change from the individual's own baseline | Expected-change marker: insulin fell 18% in one case |
| QTc interval (electrocardiogram) | No established target; track change from the individual's own baseline | Safety check: relevant with QT-prolonging drugs |
Cadence: Baseline before starting, then 4 weeks, 12 weeks, then every 6–12 months; the cadence reflects common practice rather than evidence, as trials ran only 4–8 weeks